Japanese drug major Daiichi Sankyo (TYO: 4568) has sold all of its shares of Indian drugmaker Sun Pharmaceutical Industries (BSE: 524715), sending Sun’s shares down 10%.
In March Daiichi Sankyo received the shares of Sun Pharma following the completion of Sun Pharma’s merger with Ranbaxy Laboratories (BSE:500359), of which it had been majority shareholder. Daiichi announced today that it has sold all 214,969,058 shares after it said on Monday: “From the perspective of the improvement of corporate value, Daiichi Sankyo has performed a review of the Sun Pharma shares and reached a conclusion to sell the shares entirely or partially. After the sale, Daiichi Sankyo will not be a shareholder of Sun Pharma. However, the existing business partnership with Sun Pharma will remain unchanged.”
The company said it will announce any result of the sale in its end of year financial results.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze